|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 21, 2019 ) Growth in this market is driven by the rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers. On the other hand, the availability of alternative detection technologies is expected to limit market growth during the forecast period.
Market Size
The global ELISpot and FluoroSpot Assay Market is projected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2%.
To know about the assumptions considered for the study download the pdf brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124350584
“Assay Kits are expected to account for the largest share of the market in 2018”
By product type, the ELISpot and FluoroSpot market is segmented into assay kits, analyzers, and ancillary products. The assay kits segment accounted for the largest share in 2018, and this trend is expected to continue during the forecast period. The rising incidence of chronic diseases and technological advancements are driving the growth of this product segment.
“Increasing use of ELISpot kits in diagnostic applications in 2018”
Based on the applications, the ELISpot and FluoroSpot market is segmented into diagnostic and research applications. The diagnostics applications segment is further classified into infectious diseases and transplants. In 2018, the diagnostic segment is expected to account for the larger share of the market. The large share of this segment is attributed to the rising global prevalence of infectious diseases and the increasing use of ELISpot kits for disease diagnosis.
“Hospitals and clinical laboratories are expected to be the largest end users in the ELISpot and FluoroSpot market in 2018“
By end user, the ELISpot and FluoroSpot market is segmented into hospitals & clinical laboratories, research institutes, and biopharmaceutical companies. The hospitals & clinical laboratories segment is expected to account for the largest market share in 2018 while the research institutes segment is projected to grow at the highest CAGR during the forecast period.
Recent Developments
• In 2018, Mabtech launched IRIS analyzer
• In 2018, Mabtech launched the human IL3 ELISpot kit
• In 2017, Lophius Biosciences launched Next Gen. T Track CMV
For More Details, Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=124350584
MarketsandMarkets™
Mr. Shelly Singh
1-888-600-6441
raviraj.tak@marketsandmarkets.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
